ArticleJournal of applied clinical medical physics2026
Margin reduction and optimal prescription isodose model for liver stereotactic radiotherapy with respiratory motion.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Margin reduction and optimal prescription isodose model for liver stereotactic radiotherapy with respiratory motion.Journal of applied clinical medical physics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to establish a framework for optimizing planning target volume (PTV) margins in liver SBRT using virtual 4DCT (v4DCT), by introducing the concept of the Dosimetric Coverage Amplitude (DCA) to quantify motion tolerance and deriving an Optimal Margin (OM) that balances tumor coverage with normal-tissue sparing.
methodsVMAT plans were developed using a whole-body phantom with a virtual tumor, ensuring that the prescription dose corresponded to D
resultsDCA analysis revealed that GTV dose coverage was maintained for respiratory motion amplitudes up to 1.9-2.2 times larger than the conventional PTV margin of 10 mm. Taking into account GTV dose coverage, average GTV dose relative to the 80%-static reference, and normal-tissue dose, the 60% isodose plan was identified as the optimal prescription level. From this plan, the OM was calculated as 5.6 mm, representing a 44% reduction compared with the conventional 10-mm PTV, while maintaining GTV coverage and minimizing liver dose. This margin reduction was attributed to the steeper dose gradient associated with prescribing to a lower isodose level. The v4DCT approach enabled the generation of multiple respiratory phase images, allowing quantitative evaluation of motion-induced dose distribution and optimization of margins based on respiratory variability.
conclusionThe proposed v4DCT-based framework demonstrated that the 60% isodose plan provided the optimal balance between tumor coverage and normal-tissue sparing, yielding an OM of 5.6 mm (44% reduction compared with the conventional 10-mm PTV). This approach offers a clinically applicable strategy for margin reduction in liver SBRT while maintaining robust dosimetric coverage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.